List view / Grid view

ForteBio

Filter the results

 

article

Antibody therapeutics for COVID-19

10 September 2020 | By

In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…

article

Defusing antibody neutralisers in AAV gene therapy

10 September 2020 | By

Adeno-associated virus (AAV)-mediated gene therapies allow for the treatment of a growing number of diseases; however, the presence of neutralising antibodies can lead to limitations of this technology, particularly for patients who may be excluded due to these pre-existing or developing neutralising antibodies. Recently, a study was published in Nature…

article

Antibodies In-Depth Focus 2020

8 September 2020 | By

Included in this in-depth focus are articles on antibody therapeutics to treat COVID-19, how AAV antibodies can be neutralised, the role of antibodies in cancer therapy and bispecific antibodies for immuno-oncology drugs.

article

Screening In-Depth Focus 2020

26 May 2020 | By

Included in this in-depth focus are articles on how high-throughput screening can be used to identify lead compounds, using chemoinformatics as a map to guide drug discovery and a novel in vitro model to screen potential treatments for non-alcoholic fatty liver disease (NAFLD).

whitepaper

Application note: A rapid method to quantitatively screen bispecific antibodies using Protein A and HIS1K biosensors

26 March 2020 | By

Scientists at Celgene Corporation developed a screening process incorporating the Octet® HTX system to identify pools and clones with higher concentrations of bispecific antibodies. Higher throughput was achieved from the multiple simultaneous measures possible on the Octet system and rapid assay times, such as binding optimisation in only 10 minutes.…